Zevra Therapeutics Management
Management criteria checks 4/4
Zevra Therapeutics' CEO is Neil McFarlane, appointed in Oct 2023, has a tenure of 2.67 years. total yearly compensation is $3.78M, comprised of 19.3% salary and 80.7% bonuses, including company stock and options. directly owns 0.66% of the company’s shares, worth $5.24M. The average tenure of the management team and the board of directors is 2.4 years and 3.2 years respectively.
Key information
Neil McFarlane
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 19.28% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.7% |
| Management average tenure | 2.4yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Narrative Update • Jun 18
ZVRA: Extended Rare Disease IP Runway Will Drive Future Upside Potential
Analysts have raised the fair value estimate for Zevra Therapeutics to $35 from $26, aligning it with updated Street price targets in the $27 to $35 range, as they incorporate extended Miplyffa intellectual property protection and a higher future P/E assumption into their models. Analyst Commentary Recent research updates on Zevra Therapeutics cluster around one theme: bullish analysts are reassessing the stock’s upside as they factor in longer intellectual property protection for Miplyffa and refine their cash flow models.
New Narrative • Jun 09
Discounted Exit Multiple Approach (DEM)
Disclaimer: This financial analysis is for informational purposes only and does not constitute investment advice. Zevra Therapeutics is a rare disease pharmaceutical company fundamentally driven by a single commercial product.Narrative Update • Jun 03
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have raised their average price target for Zevra Therapeutics to $23 from $22, citing early Miplyffa adoption trends, positive views on potential expansion opportunities, and ongoing adjustments to growth, margin and P/E assumptions in their models. Analyst Commentary Bullish analysts are leaning into a constructive view on Zevra Therapeutics, framing the updated US$23 average price target as grounded in observable Miplyffa adoption trends and modeled upside from expansion opportunities.Narrative Update • Apr 23
ZVRA: NPC Diagnosis Expansion And EU Decision Will Drive Future Upside Potential
Narrative Update: Zevra Therapeutics The updated analyst price target for Zevra Therapeutics is now $23, a $1 increase, as analysts point to the launch progress of Miplyffa, expectations for continued U.S. market penetration, and potential future catalysts including EU approval, patent term extension, and celiprolol development in VEDS. Analyst Commentary Bullish analysts are highlighting Zevra Therapeutics as a name where current valuation is closely linked to the rollout of Miplyffa and a set of identifiable potential catalysts.Narrative Update • Apr 08
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have maintained Zevra Therapeutics' fair value estimate at $26.00, with slight tweaks to growth, margin, and future P/E assumptions. Recent Street research highlights a $23 price target, supported by views that current pricing reflects conservative Miplyffa adoption and potential upside from broader patient reach and future regulatory or pipeline milestones.Narrative Update • Mar 24
ZVRA: Expanding NPC Diagnosis And EU Decision Will Drive Future Upside
Analysts have kept Zevra Therapeutics' fair value estimate steady at $26.00 while updating their assumptions on Miplyffa's launch trajectory and potential upside from EU approval, expanded U.S. adoption, and celiprolol optionality, which they note is reflected in Street price targets moving toward $23.00. Analyst Commentary Bullish analysts are framing Zevra's current share price as tied closely to conservative expectations for Miplyffa, largely anchored to the already diagnosed U.S. Niemann Pick type C population.Seeking Alpha • Mar 10
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model
Summary Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa’s commercial launch. Miplyffa’s rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA’s strong commercial momentum. ZVRA trades at discounted valuation multiples (16.9x forward P/E, 10.7x EV/EBIT), reflecting market caution over one-time income and earnings sustainability. Global expansion, especially pending EMA review and early international patient access, positions ZVRA for further upside beyond its U.S.-driven growth. Read the full article on Seeking AlphaNarrative Update • Mar 10
ZVRA: Growing NPC Access And Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their $26.00 price target for Zevra Therapeutics, citing updated assumptions that reflect slightly different estimates for revenue growth, profit margins, and future P/E, without materially changing their overall view of the stock's valuation. What's in the News Zevra Therapeutics appointed Justin Renz as Chief Financial Officer, effective March 9, 2026.Narrative Update • Feb 24
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have kept their Zevra Therapeutics price target steady at $26.00. This points to largely unchanged fair value assumptions, even as they refine inputs such as revenue growth, profit margins and future P/E expectations.Narrative Update • Feb 09
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their price target on Zevra Therapeutics at $26.00, citing only modest tweaks to assumptions around revenue growth, profit margins, the discount rate, and future P/E that did not materially change their overall view. What's in the News Zevra presented four posters at the 22nd Annual WORLDSymposium highlighting new data on MIPLYFFA (arimoclomol) for Niemann Pick Disease Type C.Narrative Update • Jan 26
ZVRA: Expanded Access Deal Will Support Long-Term Rare Disease Upside
Narrative Update: Zevra Therapeutics Analyst Price Target The analyst price target for Zevra Therapeutics is now set at US$26.00. Analysts cite small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates as key drivers for the updated view.Narrative Update • Jan 11
ZVRA: Expanded Rare Disease Access Agreement Will Support Long-Term Upside
Analysts have maintained their price target for Zevra Therapeutics at US$26.00, citing only modest adjustments to assumptions around revenue growth, profit margins and future P/E. Taken together, these changes do not alter their overall view of the company’s valuation.Narrative Update • Dec 26
ZVRA: Future Rare Disease Portfolio Will Support Long-Term Upside
Analysts have modestly increased their price target on Zevra Therapeutics to $26.00 per share, citing slightly stronger long term revenue growth and profit margin assumptions, alongside a marginally lower projected future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Narrative Update • Dec 12
ZVRA: Future Rare Disease Approvals Will Drive Long-Term Upside
Analysts have reduced their price target on Zevra Therapeutics by 3.00 dollars to 26.00 dollars, citing expectations for slower revenue growth, slightly lower profit margins, and a modestly higher discount rate, partially offset by a lower anticipated future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Analysis Article • Nov 08
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a mediocre week for Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders, with the stock dropping 13% to...Analysis Article • Nov 03
Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Sep 08
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Jul 10
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 26% gain in the last month...Analysis Article • May 22
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders would be excited to see that the share price has had a great...
New Narrative • Apr 29
MIPLYFFA Launch Will Spark European Expansion In 2025
Successful MIPLYFFA launch and European expansion plans indicate potential revenue growth and stable streams through strong demand and patient engagement.Analysis Article • Mar 10
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...Analysis Article • Nov 15
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
As you might know, Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) last week released its latest third-quarter, and things did...Analysis Article • Aug 30
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 34% gain in the last month...Analysis Article • Jul 12
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders have had their patience rewarded with a 26% share price jump in...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$117m |
| Dec 31 2025 | US$4m | US$729k | US$78m |
| Sep 30 2025 | n/a | n/a | US$30m |
| Jun 30 2025 | n/a | n/a | -US$3m |
| Mar 31 2025 | n/a | n/a | -US$92m |
| Dec 31 2024 | US$5m | US$700k | -US$106m |
| Sep 30 2024 | n/a | n/a | -US$90m |
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensation vs Market: Neil's total compensation ($USD3.78M) is about average for companies of similar size in the US market ($USD3.58M).
Compensation vs Earnings: Neil's compensation has been consistent with company performance over the past year.
CEO
Neil McFarlane (53 yo)
2.7yrs
Tenure
US$3,782,042
Compensation
Mr. Neil F. McFarlane serves as the Member of Board of Managers of HCRx Holdings at Healthcare Royalty Management, LLC. He is in this position since January 2024. He serves as President & Chief Executive O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$3.78m | 0.66% $ 5.2m | |
| Chief Legal Officer | 2yrs | US$1.57m | 0.081% $ 650.7k | |
| CFO & Treasurer | less than a year | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | 3.8yrs | no data | no data | |
| Chief People Officer | 2yrs | no data | no data | |
| Senior Vice President of Manufacturing | 3.4yrs | no data | no data | |
| Chief Commercial Officer | 3.4yrs | US$1.82m | 0.11% $ 842.0k | |
| Chief Medical Officer | 2.4yrs | US$2.52m | 0.016% $ 131.5k | |
| Senior Vice President of Regulatory Affairs & Quality | 2.4yrs | no data | no data | |
| Senior VP & Chief of Staff | 2.4yrs | no data | no data | |
| Senior VP of Finance & Corporate Controller | 9.3yrs | no data | 0.050% $ 400.0k |
2.4yrs
Average Tenure
54yo
Average Age
Experienced Management: ZVRA's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$3.78m | 0.66% $ 5.2m | |
| Independent Director | 3.2yrs | US$243.99k | 0% $ 0 | |
| Independent Chair | 4.8yrs | US$304.68k | 0.0066% $ 52.7k | |
| Member of Scientific and Medical Advisory Board | no data | no data | no data | |
| Independent Director | 3.2yrs | US$246.91k | 0.21% $ 1.7m | |
| Independent Director | 3.2yrs | US$249.68k | 0.0030% $ 24.3k | |
| Chairman of Scientific and Medical Advisory Board | 19.4yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Co-Chair of Physician Advisory Council | 12.7yrs | no data | no data | |
| Co-Chair of Physician Advisory Council | 12.7yrs | no data | no data | |
| Independent Director | 2.8yrs | US$252.18k | 0.034% $ 270.4k | |
| Independent Director | 2.4yrs | US$244.68k | 0.034% $ 270.4k |
3.2yrs
Average Tenure
59yo
Average Age
Experienced Board: ZVRA's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 05:18 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zevra Therapeutics, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |
| Kambiz Yazdi | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |